| Name | Title | Contact Details |
|---|
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
Creganna is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Rocky Mountain Lions Eye Bank is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gnathos Dental Products is a Union, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OrthoSensor, Inc., a leader in Sensor-Assisted Total Knee Arthroplasty, develops and commercializes intelligent orthopaedic devices and data services that provide quantitative feedback to surgeons and hospitals. The company`s intelligent orthopaedic devices utilize advanced proprietary sensor and communications technologies, coupled with the company`s innovative software products, to facilitate evidence-based decisions in orthopaedic surgery – with the goal of improving patient outcomes and potentially reducing the cost of treating musculoskeletal disease. OrthoSensor® and VERASENSE™ are trademarks of OrthoSensor, Inc.